Aeterna Zentaris (NASDAQ:AEZS) Share Price Passes Above 200-Day Moving Average – Time to Sell?

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.07 and traded as high as $3.61. Aeterna Zentaris shares last traded at $3.57, with a volume of 1,760 shares.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen assumed coverage on shares of Aeterna Zentaris in a research note on Monday, May 19th. They set a “sell” rating for the company.

Aeterna Zentaris Price Performance

The company has a market cap of $6.40 million, a P/E ratio of -0.24 and a beta of 1.55. The stock’s 50-day moving average is $3.41 and its two-hundred day moving average is $3.07.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.